MedTrace Logo

Nebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis

NCT06558461 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-08-16

No results posted yet for this study

Summary

This study aims to determine the efficacy of nebulising 3% hypertonic saline in improving clinical symptoms and reducing the length of hospital stay in infants with acute bronchiolitis.

Conditions

  • Acute Bronchiolitis

Interventions

DRUG

3% Sodium Chloride

4ml nebulized three times daily

OTHER

Standard care

Standard care

Sponsors & Collaborators

  • Can Tho University of Medicine and Pharmacy

    lead OTHER

Principal Investigators

  • Van VuTuong Le, MD · Can Tho University of Medicine and Pharmacy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-05-27
Completion
2024-05-28
FDA Drug
Yes

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06558461 on ClinicalTrials.gov